

South London and Maudsley NHS Foundation Trust: FY1819 Q3 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
17/LO/1714	224074	A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period for the prevention of first-episode of psychosis in subjects with attenuated psychosis syndrome.	17/10/2017	09/01/2018	01/12/2017	11/01/2018	07/02/2018	06/07/2018		Both
17/LO/1935	235007	Use of blue blocking glasses in mania: a feasibility study	02/10/2017	03/01/2018	03/01/2018	22/01/2018	22/01/2018	22/01/2018	15/07/2018	Sponsor
17/LO/1964	231245	Testing The Feasibility And Acceptability Of A New Personalised Form Of Cognitive Remediation Therapy (pCRT) For People With Psychosis	25/10/2017	17/01/2018	17/01/2018	08/02/2018	08/02/2018	08/02/2018	11/09/2018	Sponsor
18/LO/0168	238641	COMPASS Study: A study to examine the use of Virtual Reality (VR) to enhance self-compassion and motivation in a group of patients with Anorexia Nervosa.	20/12/2017	27/02/2018	27/02/2018	02/05/2018	02/05/2018	02/05/2018	10/05/2018	Sponsor
18/LO/0492	242325	Feasibility and acceptability of a randomised controlled trial of an integrated group intervention to reduce intimate partner violence perpetration among men receiving treatment for substance use	01/03/2018	06/03/2018	10/04/2018	02/05/2018	02/05/2018	02/05/2018	17/07/2018	Sponsor
18/SC/0104	240005	EFFIP (E-support for Families and Friends of Individuals affected by Psychosis): A randomised controlled trial of a co-produced online intervention for carers	07/02/2018	01/03/2018	02/02/2018	15/03/2018	15/03/2018	15/03/2018	30/03/2018	N/A
18/LO/0538	236451	Evaluating the feasibility and acceptability of a novel mobile intervention targeting social cognition in individuals with psychosis.	26/02/2018	30/04/2018	07/06/2018	03/07/2018	03/07/2018	03/07/2018	31/08/2018	Sponsor

South London and Maudsley NHS Foundation Trust: FY1819 Q3 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
17/SC/0578	234953	Interventional, randomised, double-blind, active-controlled study on the efficacy of Lu AF35700 in patients with early-in-disease or late-in-disease treatment resistant schizophrenia	19/01/2018	29/03/2018	25/01/2018	17/04/2018	19/04/2018	23/04/2018	29/06/2018	Neither
18/LO/0128	240068	A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic (Aripiprazole, Olanzapine, Quetiapine, or Risperidone)	18/04/2018	20/04/2018	14/03/2018	04/06/2018	07/06/2018	08/06/2018		Sponsor
18/LO/0684	238377	Can imagination change upsetting memories of trauma?	22/03/2018	23/05/2018	23/05/2018	04/07/2018	04/07/2018	04/07/2018	13/08/2018	NHS Provider
18/LO/0362	238744	The Early Youth Engagement in first episode psychosis (EYE-2) study: pragmatic cluster randomised controlled trial of implementation, effectiveness & cost effectiveness of a team-based motivational engagement intervention to improve engagement	14/05/2018	14/05/2018	11/05/2018	08/08/2018	08/08/2018	26/10/2018	09/08/2018	Sponsor
18/LO/1013	244997	Craving Induction and Imagery-based Coping for Cocaine Use Disorder: Clinical Study	16/05/2018	30/07/2018	30/07/2018	10/09/2018	10/09/2018	10/09/2018	14/11/2018	Both
17/YH/0329	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease	29/08/2018	17/08/2018	28/11/2017	21/08/2018	29/08/2018	29/08/2018		Neither

South London and Maudsley NHS Foundation Trust: FY1819 Q3 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
18/WA/0088	229419	A Phase 3, multicenter, randomized, double-blind, placebocontrolled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/ quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type.	25/04/2018	19/07/2018	31/07/2018	27/07/2018	02/08/2018	07/08/2018		Neither
18/LO/0575	213457	A Validation Study of a computerized, Artificial Intelligence assisted cognitive assessment test compared to a widely used cognitive assessment test and specialist clinical diagnosis in patients with Alzheimer's Dementia and Mild Cognitive Impairment	15/06/2018	28/08/2018	15/06/2018	31/08/2018	04/09/2018	05/09/2018	25/09/2018	N/A
18/EE/0151	244573	A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies (DELPHIA)	24/07/2018	19/09/2018	31/07/2018	19/09/2018	03/10/2018	03/10/2018		Neither
18/LO/0287	235360	The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)	24/07/2018	25/07/2018	24/07/2018	03/08/2018	02/08/2018	31/08/2018		NHS Provider
18/LO/1001	246304	A Global PRospective, Multi-cEnter, ObServational post-markeT Study tO assess shoRt, mid and long-term Effectiveness and efficiency of VNS Therapy® as adjunctive therapy in real-world patlents with diFFicult to treat dEpression.	14/05/2018	04/09/2018	13/06/2018	05/09/2018	12/09/2018	13/09/2018	12/10/2018	N/A
18/LO/0731	246135	The Effects of Psilocybin on Cognitive Function in Healthy Participants	24/07/2018	25/07/2018	24/07/2018	03/08/2018	02/08/2018	06/08/2018	17/08/2018	N/A

South London and Maudsley NHS Foundation Trust: FY1819 Q3 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
18/LO/1722	249936	Telephone delivered Incentives for Encouraging adherence to Supervised methadone consumption: a feasibility study for a RCT of clinical and cost effectiveness (TIES)	05/09/2018	11/10/2018	12/11/2018	17/12/2018	17/12/2018	17/12/2018		NHS Provider
18/LO/1683	241656	A randomised controlled feasibility study of food related computerised attention training for obesity versus active (mindfulness-based intervention MBI) and waiting list control (FOCUS)	04/09/2018	13/11/2018	13/11/2018	10/01/2019	10/01/2019	10/01/2019		NHS Provider
18/EM/0335	240188	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents with Autism Spectrum Disorders.	23/05/2018	12/11/2018						N/A
18/NW/0648	244170	ICARUS: An Investigation of Approach Bias Modification Training and Transcranial Direct Current Stimulation in Binge Eating Disorder	28/08/2018	07/11/2018	07/11/2018					N/A
18/LO/1634	244432	A pilot randomised controlled trial of Mindfulness Based Cognitive Therapy compared to Psychoeducation in adults with Attention-Deficit/Hyperactivity Disorder	29/08/2018	28/11/2018	28/11/2018	04/01/2019	04/01/2019	04/01/2019		N/A
18/WS/0040	204214	A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia.	13/11/2018	11/12/2018	19/04/2018	12/12/2018	18/12/2018	19/12/2018		N/A